[A20-95] Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2021
Project no.:
A20-95
Commission:
Commission awarded on 16.11.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adults with moderate to severe atopic dermatitis who are candidates for systemic therapy
Added benefit not proven for either of both research questions (longterm/continued systemic therapy indicated or not indicated)
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-14 | Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-114 | Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-108 | Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-109 | Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-113 | Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |